Left atrium (LA) gradually enlarges with the time course of atrial fibrillation (AF). The aim of this study was to examine whether the renin-angiotensin system (RAS) inhibitor could prevent LA remodelling in patients with chronic AF.
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, 1, 2 and the left atrium (LA) gradually enlarges with the time course of AF. 3, 4 In addition, LA dilatation is a risk factor for heart failure or cerebral infarction. 5 -9 Recently, several studies have
shown that renin-angiotensin system (RAS) inhibitors prevented the electrical and structural remodelling of LA, 10, 11 and the appearance and persistence of AF. 12 However, no studies have been done to find whether RAS inhibitors affect LA remodelling in chronic AF. The purpose of this study is to determine the effect of RAS inhibitors on LA remodelling in patients with chronic non-valvular AF. ,45%], permanent pacemaker, congenital heart disease, and moderate or severe valvular heart disease were excluded. Moreover, patients with new development of hypertension during follow-up of this study or patients with changed antihypertensive medication were excluded. A total of 41 patients were included and divided into two groups: the RAS group (23 patients) taking RAS inhibitors [angiotensin-converting enzyme-inhibitor (ACE-I) or angiotensin II receptor blocker (ARB)] and the non-RAS group (18 patients) without taking these drugs. The baseline clinical characteristics of both groups are shown in Table 1 .
Methods

Echocardiography
Echocardiography was performed using SIEMENS SEQUOIA 512 ultrasound instrument equipped with a sector transducer (carrier frequency of 2.5 MHz). The following echocardiographic parameters at the beginning and the end of follow-up were compared between the groups: LA diameter, LA expansion fraction, LA volume, LV end-diastolic volume, LVEF, LV mass index, peak early diastolic velocity (E) of the LV inflow, peak early diastolic longitudinal velocity (e ′ ) of the mitral annulus, and the ratio of E to e ′ (E/e ′ ). The LA diameter was measured as the maximum dimension along the parasternal long-axis view from two-dimensionally guided M-mode tracings. The LA expansion fraction was derived from the following formula: maximum LA diameter at end systole divided by minimum LA diameter at end diastole ( Figure 1A) . The LA volume was measured using single plane Simpson's method in the apical view showing the largest LA area ( Figure 1B) . The LA volume was corrected for body surface area (LA volume index). LV enddiastolic and end-systolic volumes (LVEDV and LVESV, respectively) were obtained using a modified biplane Simpson's method from apical four-and two-chamber views, 13 and the LVEF was calculated by the following formula: (LVEDV7 2 LVESV)/LVEDV × 100 (%). The LV mass index was calculated using Devereux's formula. 14 LV inflow velocity curve was obtained from the apical long-axis view with the pulsed Doppler sample volume positioned at the tips of the mitral leaflets. 15 The peak early diastolic velocity of mitral inflow was obtained at the septal and lateral sites of the mitral annulus using pulsed Doppler tissue imaging and the average of those two values was used to define the e ′ velocity. Each echocardiographic parameter was measured on the average of five consecutive cardiac cycles. Percent changes of each echocardiographic parameter were calculated from the value at the end of follow-up divided by the value at the beginning of follow-up. LA remodelling was defined as the increase of the LA volume during the follow-up period.
Statistical analysis
Values were expressed as means + standard deviations. Statistical analysis was performed using StatView 5.0. Differences between the groups were evaluated using the unpaired t-test for continuous variables and the x 2 test for categorical variables. Multivariate linear regression analysis with step-wise method was used to test for independent associations with LA remodelling. A level of P , 0.05 was accepted as statistically significant. 
Results
Baseline clinical characteristics
The patients in the RAS group took either ACE-I or ARB. No patient took both of them. Although hypertension was more frequent in the RAS group, the mean systolic and diastolic blood pressures were similar and under control in the two groups and heart rate was similar and under control in the two groups. The two groups also had similar age and gender and BMI and similar prevalence of diabetes, heart failure, and the use of satins, diuretics, and aldosterone blockers. The mean follow-up period was similar in the RAS and non-RAS groups: 60 + 35 vs. 63 + 35 months (n.s.)
Echocardiographic data at the beginning and the end of follow-up
At the beginning of follow-up, there were no significant differences between the groups, concerning the LA diameter, LA volume index, LA expansion fraction, LVEDV, LVEF, LV mass index, E, e ′ , and E/e ′ between the groups ( Table 2) . At the end of follow-up, the LA expansion fraction was significantly greater in the RAS group than in the non-RAS group, but the other parameters did not show significant differences between the groups ( Table 3) .
Changes of echocardiographic data during follow-up
LA volume index increased in both groups of patients, although the greater increase was observed in the non-RAS group (percent change: 119 + 24 vs. 146 + 33%; P , 0.05; Table 4 ). LA expansion fraction remained almost unchangeable in the RAS group, but decreased significantly in the non-RAS group (percent change: 99 + 6 vs. 93 + 8%; P , 0.05). The E/e ′ ratio showed little change in RAS group, but increased significantly in the non-RAS group (percent change: 103 + 34 vs. 140 + 58%; P , 0.05). There were no significant differences in the percent changes of LVEDV, LVEF, and LV mass index during follow-up periods between the groups.
Univariate and multivariate regression analyses
Multivariate linear regression analysis with step-wise method was performed, revealing that the use of RAS inhibitors was inversely associated with the LA volume index increase, which suggests a protective effect of these drugs on LA structural remodelling (coefficient of regression: 20.37; P ¼ 0.01; Table 5 ).
Discussion
This study demonstrated for the first time that the long-term administration of RAS inhibitors attenuated the increase of LA volume, decrease of LA expansion fraction, and an increase in E/e ′ in patients with chronic non-valvular AF. Enlargement of LA volume indicates structural remodelling of the LA, that is, progression of fibrous changes in the atrial tissue. 16, 17 Decrease in LA expansion fraction indicates progression of LA dysfunction, 18 and increase in E/e ′ indicates elevation of LV filling pressure.
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The relationship between RAS inhibitors and AF has been the subject of some studies. Van Den Berg et al. 20 showed that an ACE-I, lisinopril, decreased the recurrence of AF after cardioversion in patients with congestive heart failure. Pedersen et al. 21 observed
that an ACE-I, trandolapril, reduced the incidence of AF in patients with LV dysfunction after myocardial infarction. In addition, Goette et al. 22 difference in the use of these drugs between the RAS and the non-RAS group.
Enlargement of the LA volume and the occurrence of AF may also be brought by increased stiffness of the LV. We cannot exclude the possibility that the beneficial effect on LA remodelling could be a consequence of an improvement of the LV diastolic properties and not a direct effect of the drug. However, e ′ (representing LV active relaxation 24 ) was similar in the two groups at the beginning and end of follow-up, remaining practically unchangeable during follow-up in both groups, which argues in favour of a direct effect of the RAS inhibitor on LA remodelling. Although e ′ remains constant, E/e ′ ratio (representing LV filling pressure 18 ) increases in the non-RAS group. Known factors contributing to increases of E/e ′ include systemic vascular resistance, cardiac output, LV systolic and diastolic function, and LA function. In this study, however, there were no significant differences on LVEDV, LV mass index, and LVEF between the groups at the beginning and the end of follow-up or in the percent changes of those values during follow-up. Also blood pressure was similar between the groups at the beginning of follow-up and no patient was admitted for congestive heart failure during follow-up. For these reasons, we favour the hypothesis of a direct beneficial effect of the RAS inhibitor on LA remodelling and consequently on LV filling pressure.
Moss et al. 6 and Caplan et al. 7 reported that the enlargement of LA volume might increase the risk of stroke in patients with chronic AF. The results of this study suggest that the long-term administration of RAS inhibitors may have a preventive effect against stroke in chronic AF. Further prospective studies are necessary to demonstrate whether the preventive effect of LA remodelling by RAS inhibitors could lead to reduction of stroke risk in patients with chronic non-valvular AF.
Limitations
This study has a few limitations. First, we could not perform pathological examinations of the LA tissue to measure fibrotic changes quantitatively. However, either volume or expansion fraction of the LA is thought to be a useful marker for LA remodelling. 16 -18 Thus, the follow-up increase in LA volume was used as an indicator of LA remodelling in this study. Second, we identified patients taking ACE-I or ARB as the RAS group. In this study, both ACE-I and ARB had beneficial effects of LA remodelling. However, the main angiotensin II-forming enzyme in human atria is chymase, but not ACE. 25 Further study is necessary to examine the difference in the effect of LA remodelling between ACE-I and ARB. Third, we did not investigate the influences of statin for LA remodelling. 26 -30 In this study, we administered statin to the patients with high total cholesterol or high -low-density lipoprotein cholesterol according to the guideline of the Japan Atherosclerosis Society. Although there was no significant difference regarding the prevalence of the use of statin between the RAS group and the non-RAS group, no other analysis of the possible influence of statins on LA remodelling was done. Further investigation on the influence of statin is needed. Last, this was a retrospective study. A large randomized prospective study is needed to clarify the clinical importance of RAS inhibitors in the management of chronic AF patients. BP, blood pressure; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LAEF, left atrial expansion fraction; E/e ′ , the ratio of peak early diastolic velocity of the mitral inflow to peak early diastolic longitudinal velocity of the mitral annulus. The bold values mean that P value is less than 0.05. LAD, left atrial dimension; LAVI, left atrial volume index; LAEF, left atrial expansion fraction; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction; E, peak early diastolic velocity of the mitral inflow; e ′ , peak early diastolic longitudinal velocity of the mitral annulus; E/e ′ , the ratio of E to e ′ . The bold values mean that P value is less than 0.05.
Conclusions
Long-term administration of RAS inhibitors may prevent structural and functional degradation of LA in patients with chronic non-valvular AF.
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